Pluristem Therapeutics Inc (PSTI): Doron Shorrer , director of Pluristem Therapeutics Inc sold 12,346 shares on May 30, 2016. The Insider selling transaction was reported by the company on Jun 6, 2016 to the Securities and Exchange Commission. The shares were sold at $1.52 per share for a total value of $18,784.44 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Feb 24, 2016, Zami Aberman (CEO) purchased 5,000 shares at $1.33 per share price.On Feb 22, 2016, Yaky Yanay (CFO) purchased 5,000 shares at $1.20 per share price.Also, On Feb 17, 2016, Doron Shorrer (director) purchased 12,346 shares at $0.81 per share price.On Sep 24, 2015, Israel Ben-yoram (director) sold 30,000 shares at $2.10 per share price.
Pluristem Therapeutics: On Friday, Jun 3, 2016 heightened volatility was witnessed in Pluristem Therapeutics which led to swings in the share price. The shares opened for trading at $1.53 and hit $1.58 on the upside , eventually ending the session at $1.57, with a gain of 1.62% or 0.025 points. The heightened volatility saw the trading volume jump to 54,497 shares. The 52-week high of the share price is $2.84 and the company has a market cap of $126 M . The 52-week low of the share price is at $0.71.
Pluristem Therapeutics Inc. (Pluristem) is a bio-therapeutics company developing off-the-shelf allogeneic cell therapy products for the treatment of multiple ischemic and inflammatory conditions. The Company focuses on cardiovascular orthopedic pulmonary hematological and women’s health diseases. The Company is focused on the research development clinical trials and manufacturing of cell therapeutics and related technologies. The Company’s placenta expanded (PLX) cells are intended to function as a platform that releases a number of therapeutic proteins in response to various local and systemic inflammatory and ischemic signals that are generated by the patient’s own body. PLX cells are grown using its three-dimensional (3D) micro environment technology which produces a product that requires no tissue matching prior to administration. Its PLX products are in clinical-stage development for multiple indications.